J&J’s Rybrevant Results Provide Encouragement After Interim Analysis Sparked Jitters

 
• By Alaric DeArment

The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.

J&J announced positive topline results from the Phase III MARIPOSA study of Rybrevant • Source: Shutterstock

More from Clinical Trials

More from R&D